Clinical Trials | October 25, 2025
Sanofi’s Efdoralprin Alfa shows superiority in phase 2 Alpha-1 antitrypsin deficiency study
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
The platform is being introduced to expand access to treatments for people living with chronic conditions
Subscribe To Our Newsletter & Stay Updated
